Factor XIII

Factor XIII is the last factor activated in the coagulation cascade. After fibrinogen is converted to fibrin monomers by thrombin, these monomers polymerize via hydrogen bonds to form a soft, unstable clot. Thrombin also activates Factor XIII (by cleaving it to XIIIa) in the presence of calcium, and XIIIa then catalyzes the formation of covalent cross-links between fibrin monomers (specifically gamma-glutamyl-lysine bonds), converting the soft clot into a hard, cross-linked, stable clot resistant to fibrinolysis. This cross-linking also incorporates alpha-2-antiplasmin into the clot, further protecting it from premature degradation.

Clinically, Factor XIII deficiency (congenital or acquired) presents uniquely among coagulation factor deficiencies: PT and PTT are classically NORMAL because these tests measure clot formation, not clot stabilization. The classic presentation includes delayed umbilical cord bleeding in neonates, poor wound healing, recurrent miscarriages, and delayed-onset bleeding after trauma or surgery (since initial clot forms normally but is unstable and breaks down). Diagnosis requires a specific clot solubility test (clots dissolve in 5M urea or monochloroacetic acid due to lack of cross-linking) or quantitative Factor XIII assay. Treatment involves Factor XIII concentrate, cryoprecipitate, or fresh frozen plasma.

Factor XIII is also a substrate target of certain anti-fibrinolytic therapies and is relevant to wound healing physiology, as it plays roles beyond hemostasis including tissue repair, angiogenesis, and placental implantation (explaining the association with recurrent miscarriage in deficiency states).